Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4685
Title: Streptococcus pneumoniae and chronic endobronchial infections in childhood
Authors: Smith-Vaughan, H. C.
Hare, K. M.
Leach, A. J.
Anne Chang 
Grimwood, K.
Issue Date: 2017
Source: 52, (12), 2017, p. 1532-1545
Pages: 1532-1545
Journal: Pediatric Pulmonology
Abstract: Streptococcus pneumoniae (pneumococcus) is the main cause of bacterial pneumonia worldwide and has been studied extensively in this context. However, its role in chronic endobronchial infections and accompanying lower airway neutrophilic infiltration has received little attention. Severe and recurrent pneumonia are risk factors for chronic suppurative lung disease (CSLD) and bronchiectasis; the latter causes considerable morbidity and, in some populations, premature death in children and adults. Protracted bacterial bronchitis (PBB) is another chronic endobronchial infection associated with substantial morbidity. In some children, PBB may progress to bronchiectasis. Although nontypeable Haemophilus influenzae is the main pathogen in PBB, CSLD and bronchiectasis, pneumococci are isolated commonly from the lower airways of children with these diagnoses. Here we review what is known currently about pneumococci in PBB, CSLD and bronchiectasis, including the importance of pneumococcal nasopharyngeal colonization and how persistence in the lower airways may contribute to the pathogenesis of these chronic pulmonary disorders. Antibiotic treatments, particularly long-term azithromycin therapy, are discussed together with antibiotic resistance and the impact of pneumococcal conjugate vaccines. Important areas requiring further investigation are identified, including immune responses associated with pneumococcal lower airway infection, alone and in combination with other respiratory pathogens, and microarray serotyping to improve detection of carriage and infection by multiple serotypes. Genome wide association studies of pneumococci from the upper and lower airways will help identify virulence and resistance determinants, including potential therapeutic targets and vaccine antigens to treat and prevent endobronchial infections. Much work is needed, but the benefits will be substantial.L6193518692017-11-27
2017-11-30
DOI: 10.1002/ppul.23828
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L619351869&from=exporthttp://dx.doi.org/10.1002/ppul.23828 |
Keywords: drug targeting;genome-wide association study;Haemophilus influenzae;human;immune response;lower respiratory tract;lung disease;minimum inhibitory concentration;nasopharynx;priority journal;serotyping;Streptococcus pneumoniae;treatment outcome;pathogenesis;amoxicillinamoxicillin plus clavulanic acid;azithromycin;beta lactam antibiotic;cephalosporin derivative;macrolide;penicillin derivative;placebo;Pneumococcus vaccine;antibiotic resistance;article;bacterial colonization;bacterial pneumonia;bacterial virulence;bacterium identification;bacterium isolation;bronchiectasis;disease severity
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

100
checked on Mar 25, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.